## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.9% in upper entry zone (3.0-6.0%), top 9% cross-sectional ranking. Short-term MRS_5 (2.6%) confirms momentum alignment. Strong momentum (+3.2% 5-day acceleration). Outperforming sector by 4.5%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.08)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders**
- Source: MyHighPlains.com | 20251214T100844 | Bearish | Relevance: 100%
- A securities class action lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) by Levi & Korsinsky, LLP, on behalf of shareholders who suffered losses between August 8, 2024, and February 26, 2025. The lawsuit alleges Viatris misrepresented the impact of a failed FDA inspection at its Indore, India facility, leading to a significant stock price drop following disappointing 2025 guidance. Shareholders are encouraged to seek recovery for their losses.

**2. Is Viatris Stock Outperforming the Dow?**
- Source: Barchart.com | 20251215T153554 | Neutral | Relevance: 100%
- Viatris Inc. (VTRS) is a large-cap healthcare company valued at $13.4 billion, trading 7.7% below its 52-week high. While it has outperformed the Dow Jones Industrial Average with a 22.9% rise in the past three months, VTRS has lagged in longer terms, declining 6.6% over the past 52 weeks and 5.3% YTD. Despite recent Q3 earnings showing a revenue increase but EPS decline, analysts maintain a "Moderate Buy" rating with a 6.6% premium target.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.7x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.5B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.74 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.7 |
| Current P/E | 5.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.7% to 5.9% (+3.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 91st percentile. MRS_5 at 2.6% confirms short-term momentum alignment. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.88% (CS: 91) | Strong |
| RSI_14 | 72.9 | Overbought |
| MACD Histogram | 0.09 | Bullish |
| vs SMA20 | 1.071x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.228x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $11.66
- **Stop Loss:** $11.08 (5.0% risk)
- **Target:** $12.53 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2068
- **Position Value:** $24,112.88
- **Portfolio %:** 24.11%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*